ZVRA (zevra.com) מחיר לרווח עתידי

Zevra Corp - לוגו גרפי של המנפיק ZVRA

The market dynamics of Zevra Therapeutics (ZVRA) demonstrate a current P/E ratio of 10.20. Zevra Therapeutics focuses on therapies for rare CNS pathologies, bringing together top-tier experts who receive competitive compensation and scientific resources. The business relies on exclusive FDA rights and patent protection, which blocks competitors from entering the market and protects sales from generic drug copies.

ZVRA - יחס מחיר לרווח חזוי Zevra Therapeutics Inc בטווח 28.04.2023 - 16.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור zevra.com (ZVRA)

- מחיר נוכחי ושווי מניות חזוי:
ניתוח כל מדדי החברה:ZVRA Kempharm
מוצר ממותג של Zevra Therapeutics

Zevra Therapeutics (ZVRA) is transitioning toward stable cash flow through the commercialization of drugs for the treatment of rare neurological pathologies. The forward P/E ratio compares the current market value of the business with expected net income for future periods. This multiple allows for an assessment of the premium paid for the potential growth in profitability. Smoothed dynamics protect capital from impulsive reactions to short-term volatility. By analyzing the company's forward P/E value, an investor determines the resilience of the business valuation to macroeconomic changes.